

Recommendations of the Advisory Committee on Immunization Practices Zoster Vaccines

Morbidity and Mortality Weekly Report

67, 103-108

DOI: [10.15585/mmwr.mm6703a5](https://doi.org/10.15585/mmwr.mm6703a5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Herpes Zoster and Diabetes Mellitus: A Review. <i>Diabetes Therapy</i> , 2018, 9, 545-550.	2.5	47
2	Zoster Vaccine Recombinant, Adjuvanted. <i>Hospital Pharmacy</i> , 2018, 53, 136-141.	1.0	3
3	Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2018, 67, 1712-1719.	5.8	22
4	Evaluating Physician Attitudes and Practices Regarding Herpes Zoster Vaccination. <i>Cornea</i> , 2018, 37, 947-951.	1.7	8
5	What are the new vaccination recommendations for herpes zoster?. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2018, 31, 14-15.	0.3	2
6	Management of vaccination in rheumatic disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 720-734.	3.3	8
7	Treatment of Trigeminal Neuralgia with Anti-viral Therapy for Zoster: A Case Report. <i>Cureus</i> , 2018, 10, e2144.	0.5	2
8	Immunization update 2018. <i>Pharmacy Today</i> , 2018, 24, 48-57.	0.0	2
9	Herpes Zoster Vaccination: An Urgent Priority. <i>Cornea</i> , 2018, 37, e57-e58.	1.7	2
10	Limited Focus in Evaluation of Vaccine Cost-effectiveness. <i>JAMA Internal Medicine</i> , 2018, 178, 1563.	5.1	0
11	Optimal Timing of Zoster Vaccination After Shingles: A Prospective Study of the Immunogenicity and Safety of Live Zoster Vaccine. <i>Infection and Chemotherapy</i> , 2018, 50, 311.	2.3	1
12	Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. <i>BMC Medicine</i> , 2018, 16, 228.	5.5	13
13	Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 11-15.	1.9	7
14	Update on Vaccinating the Patient With Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 548-560.	0.8	5
15	A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1401-1411.	2.7	9
16	Herpes Zoster Eye Disease: New Ways to Combat an Old Foe?. <i>Ophthalmology</i> , 2018, 125, 1671-1674.	5.2	13
17	Implementation of Hospital Policy for Healthcare Workers and Patients Exposed to Varicella-Zoster Virus. <i>Journal of Korean Medical Science</i> , 2018, 33, e252.	2.5	6
18	Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 363, k4029.	2.3	73

#	ARTICLE	IF	CITATIONS
19	The Economic Impact of Herpes Zoster Vaccine Disparities in Elderly United States Blacks. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2128.	2.6	2
20	Which shingles vaccine for older adults?. <i>BMJ: British Medical Journal</i> , 2018, 363, k4203.	2.3	2
21	Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1216-1247.	4.9	113
22	Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster. <i>Drugs and Aging</i> , 2018, 35, 1031-1040.	2.7	62
23	Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors. <i>International Journal of Pharmaceutics</i> , 2018, 553, 327-337.	5.2	31
24	Policy Statement. <i>Ophthalmology</i> , 2018, 125, 1813-1816.	5.2	5
25	Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. <i>Vaccine</i> , 2018, 36, 3890-3893.	3.8	52
26	Herpes zoster ophthalmicus. <i>Current Opinion in Ophthalmology</i> , 2018, 29, 328-333.	2.9	34
27	Adherence with and completion of recommended hepatitis vaccination schedules among adults in the United States. <i>Vaccine</i> , 2018, 36, 5333-5339.	3.8	32
28	Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 945-956.	3.0	16
29	Herpes Zoster. <i>Annals of Internal Medicine</i> , 2018, 169, ITC17.	3.9	49
30	Successful Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2018, 428, 1-30.	1.1	22
31	The Importance of Vaccination Against Herpes Zoster. <i>Current Ophthalmology Reports</i> , 2018, 6, 173-180.	1.2	1
32	Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine. <i>JAMA Internal Medicine</i> , 2018, 178, 1277.	5.1	12
33	Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. <i>Vaccine</i> , 2018, 36, 5037-5045.	3.8	50
34	Update From the Advisory Committee on Immunization Practices. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 93-99.	1.3	2
35	Real-World Evidence for Regulatory Decisions: Concomitant Administration of Zoster Vaccine Live and Pneumococcal Polysaccharide Vaccine. <i>American Journal of Epidemiology</i> , 2018, 187, 1856-1862.	3.4	11
36	Recommendations and barriers to vaccination in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2018, 17, 990-1001.	5.8	24

#	ARTICLE	IF	CITATIONS
37	The Who and Why of Herpes Zoster Vaccination in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1872-1875.	4.4	4
38	The Neuralgias. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 69.	4.2	13
39	Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature. <i>Frontiers in Immunology</i> , 2018, 9, 1632.	4.8	24
40	Receipt of other routinely recommended vaccines relative to receipt of seasonal influenza vaccines: Trends from medicare administrative data, 2013-2015. <i>Vaccine</i> , 2018, 36, 4399-4403.	3.8	7
41	Improving Vaccination Rates for IBD Patients Through the Use of Local Pharmacies. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e19-e19.	1.9	5
42	Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 34-44.	3.3	16
43	Adult Immunization Update. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1096.	7.4	2
44	Conjunctivitis Preferred Practice Pattern®. <i>Ophthalmology</i> , 2019, 126, P94-P169.	5.2	65
45	Risk of gout flares after vaccination: a prospective case cross-over study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1601-1604.	0.9	20
46	Successful management of visceral disseminated varicella zoster virus infection during treatment of membranous nephropathy: a case report. <i>BMC Infectious Diseases</i> , 2019, 19, 625.	2.9	14
47	A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz219.	0.9	11
48	Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. <i>Vaccine</i> , 2019, 37, 5422-5427.	3.8	22
49	Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States. <i>Expert Review of Vaccines</i> , 2019, 18, 793-811.	4.4	43
50	Vaccines for International Travel. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2314-2339.	3.0	16
51	Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. <i>Clinical Infectious Diseases</i> , 2020, 70, 1509-1515.	5.8	12
52	Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60+. <i>Journal of Pharmacy Technology</i> , 2019, 35, 258-269.	1.0	1
53	Ten years of experience with herpes zoster vaccine in primary care- how attitudes and practices have changed and what it may mean for a new zoster vaccine. <i>Vaccine</i> , 2019, 37, 5509-5512.	3.8	5
54	The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial. <i>Vaccine</i> , 2019, 37, 5877-5885.	3.8	13

#	ARTICLE	IF	CITATIONS
55	Maneuvering Clinical Pathways for Ulcerative Colitis. <i>Current Gastroenterology Reports</i> , 2019, 21, 52.	2.5	2
56	Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. <i>Vaccine</i> , 2019, 37, 6262-6267.	3.8	18
57	Comparison of adjuvants to optimize influenza neutralizing antibody responses. <i>Vaccine</i> , 2019, 37, 6208-6220.	3.8	16
58	<p>Varicella zoster virus vaccines: an update</p>. <i>ImmunoTargets and Therapy</i> , 2019, Volume 8, 15-28.	5.8	29
60	Vaccination among Medicare-fee-for service beneficiaries: Characteristics and predictors of vaccine receipt, 2014–2017. <i>Vaccine</i> , 2019, 37, 1194-1201.	3.8	18
61	Incidence and Risk Factors for Developing Herpes Zoster Among a Cohort of Patients Diagnosed With Lymphoma at a Community Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e153-e158.	0.4	3
62	Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 593-609.	5.1	31
63	The Epidemiology of Herpes Zoster and Postherpetic Neuralgia in China: Results from a Cross-Sectional Study. <i>Pain and Therapy</i> , 2019, 8, 249-259.	3.2	61
64	Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial. <i>PLoS ONE</i> , 2019, 14, e0217335.	2.5	18
65	Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. <i>Vaccine</i> , 2019, 37, 3588-3597.	3.8	8
66	Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax™ in healthy adults aged 50 years and older. <i>Vaccine</i> , 2019, 37, 3605-3610.	3.8	4
67	Vaccine-derived varicella zoster infection in a kidney transplant recipient after zoster vaccine live administration. <i>Vaccine</i> , 2019, 37, 3576-3579.	3.8	11
68	A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 102-110.	1.2	52
69	Patient report of herpes zoster pain: Incremental benefits of zoster vaccine live. <i>Vaccine</i> , 2019, 37, 3478-3484.	3.8	10
70	Selection of adjuvants for vaccines targeting specific pathogens. <i>Expert Review of Vaccines</i> , 2019, 18, 505-521.	4.4	68
71	Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion. <i>Annals of Medicine</i> , 2019, 51, 128-140.	3.8	39
72	Vaccinations in kidney transplant recipients: Clearing the muddy waters. <i>World Journal of Transplantation</i> , 2019, 9, 1-13.	1.6	21
73	Analysis of Vascular Event Risk After Herpes Zoster From 2007 to 2014 US Insurance Claims Data. <i>Mayo Clinic Proceedings</i> , 2019, 94, 763-775.	3.0	24

#	ARTICLE	IF	CITATIONS
74	The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis. <i>Vaccine</i> , 2019, 37, 2896-2909.	3.8	31
75	Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older " United States, 2019. <i>American Journal of Transplantation</i> , 2019, 19, 1232-1235.	4.7	3
76	Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older " United States, 2019. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 115-118.	15.1	35
77	Zoster Vaccination in Older Adults: Efficacy and Public Health Implications. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1239-1243.	3.6	10
78	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. <i>Cancer</i> , 2019, 125, 1301-1312.	4.1	68
79	Herpes Zoster in Pregnancy. <i>Journal of Midwifery and Women's Health</i> , 2019, 64, 230-235.	1.3	6
80	A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. <i>Annals of Internal Medicine</i> , 2019, 170, 380.	3.9	45
81	Recommended Adult Immunization Schedule, United States, 2019*. <i>Annals of Internal Medicine</i> , 2019, 170, 182.	3.9	55
82	Varicella-zoster virus post-exposure management and prophylaxis: A review. <i>Preventive Medicine Reports</i> , 2019, 16, 101016.	1.8	27
83	Which patients should receive the herpes zoster vaccine?. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2019, 32, 18-20.	0.3	1
84	Herpes Zoster Ophthalmicus Review and Prevention. <i>Eye and Contact Lens</i> , 2019, 45, 286-291.	1.6	25
85	Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2019, 219, 335-338.	4.0	19
86	Herpes Zoster Rates Continue to Decline in People Living With Human Immunodeficiency Virus but Remain Higher Than Rates Reported in the General US Population. <i>Clinical Infectious Diseases</i> , 2019, 69, 155-158.	5.8	9
87	A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 820-830.	1.9	76
88	Herpes zoster infection. <i>BMJ: British Medical Journal</i> , 2019, 364, k5095.	2.3	44
89	Risk of Herpes Zoster in Cancer Patients and the Promise of New Vaccines. <i>Journal of Infectious Diseases</i> , 2019, 220, 1-2.	4.0	6
90	Special Considerations for Vaccines and the Elderly. , 2019, , 35-53.		2
91	Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 765-771.	3.3	15

#	ARTICLE	IF	CITATIONS
92	Frequency of Herpes Zoster Vaccination Among Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 345-351.	1.9	18
93	Immunogenicity of the Varicella-Zoster Vaccine in Community-Dwelling Non-robust Elderly Individuals Compared to Robust Elderly Individuals: A Prospective Cohort Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1225-1230.	3.6	5
94	Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review. <i>Pharmacoeconomics</i> , 2019, 37, 169-200.	3.3	24
95	Cost-effectiveness of adult vaccinations: A systematic review. <i>Vaccine</i> , 2019, 37, 226-234.	3.8	79
96	The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Older Adults. <i>Clinical Infectious Diseases</i> , 2019, 69, 341-344.	5.8	55
97	Vaccine Safety. , 2019, , 1-24.		0
98	Vaccine Use in Immunocompromised Adults. , 2019, , 139-162.		1
99	Emerging Topics in Vaccine Therapeutics for Adolescents and Adults: An Update for Immunizing Pharmacists. <i>Journal of Pharmacy Practice</i> , 2020, 33, 192-205.	1.0	1
100	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , 2020, 30, 36-43.	1.8	44
101	Herpes zoster after recombinant zoster vaccine: A first case report. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 772-774.e1.	3.8	5
102	Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps. <i>Clinics in Dermatology</i> , 2020, 38, 384-396.	1.6	14
103	The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 327-334.	3.3	6
104	Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review. <i>Clinical Infectious Diseases</i> , 2020, 71, e125-e134.	5.8	60
105	The Prevention of Infections in Older Adults: Vaccination. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 207-214.	2.6	12
106	Identification of herpes zoster high-risk group using Charlson comorbidity index: A nationwide retrospective cohort study. <i>Journal of Dermatology</i> , 2020, 47, 47-53.	1.2	5
107	Shingles: Not Just a Rash. <i>Journal for Nurse Practitioners</i> , 2020, 16, 111-115.	0.8	1
108	Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2986-2991.	2.3	30
109	The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 69-82.	2.4	10

#	ARTICLE	IF	CITATIONS
110	Adherence to infectious disease screening and immunization guidelines when treating non-malignant immune-mediated hematologic disorders. <i>American Journal of Hematology</i> , 2020, 95, E72-E75.	4.1	1
111	Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 97-107.	6.7	27
112	Incidence Rate of Herpes Zoster Ophthalmicus. <i>Ophthalmology</i> , 2020, 127, 324-330.	5.2	39
113	Vaccine for the Prevention of Herpes Zoster. <i>Actas Dermo-sifilograficas</i> , 2020, 111, 67-68.	0.4	1
114	How Little We Know Herpes Zoster. <i>Journal of Infectious Diseases</i> , 2020, 222, 708-711.	4.0	6
115	Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. <i>Vaccine</i> , 2020, 38, 3489-3500.	3.8	20
116	The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence. <i>Journal of Infectious Diseases</i> , 2020, 222, 798-806.	4.0	61
117	Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition. <i>Pain</i> , 2020, 161, 361-368.	4.2	28
118	Vaccination of Adults in General Medical Practice. <i>Mayo Clinic Proceedings</i> , 2020, 95, 169-183.	3.0	20
119	&p>Current Knowledge of Vaccinations in Chronic Kidney Disease Patients</p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2020, Volume 13, 179-185.	1.8	19
120	Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1567-1575.	0.9	1
121	Vacunas en pacientes con VIH/SIDA. <i>Revista Médica Clínica Las Condes</i> , 2020, 31, 317-329.	0.2	1
122	Blistering autoimmune skin reaction following SHINGRIX vaccination in an ulcerative colitis patient: Case report and literature review. <i>Vaccine</i> , 2020, 38, 7455-7457.	3.8	8
123	MPL Adjuvant Contains Competitive Antagonists of Human TLR4. <i>Frontiers in Immunology</i> , 2020, 11, 577823.	4.8	42
124	Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 481-490.	4.4	19
125	Increasing adult immunization rates in a rural state through targeted pharmacist education. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, e301-e306.	1.5	9
126	Epidemiology and risk factors for varicella zoster virus reactivation in heart transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 23, e13519.	1.7	4
128	Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 319-327.	2.5	19

#	ARTICLE	IF	CITATIONS
129	Vaccination in Inflammatory Bowel Disease: Utility and Future Perspective. <i>Gastrointestinal Disorders</i> , 2020, 2, 175-192.	0.8	1
130	Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa274.	0.9	8
131	Immunizations in immunocompromised patients: a guide for dermatologists. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 699-723.	0.8	11
132	Identification and Characterization of CD4 ⁺ T Cell Epitopes after Shingrix Vaccination. <i>Journal of Virology</i> , 2020, 94, .	3.4	18
134	Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology. <i>Drug Safety</i> , 2020, 43, 1223-1234.	3.2	4
135	Pox Parties for Grannies? Chickenpox, Exogenous Boosting, and Harmful Injustices. <i>American Journal of Bioethics</i> , 2020, 20, 45-57.	0.9	17
136	Human Papillomavirus, Herpes Zoster, and Hepatitis B Vaccinations in Immunocompromised Patients: An Update for Pharmacists. <i>Journal of Pharmacy Practice</i> , 2020, 34, 089719002095826.	1.0	1
137	Herpes Zoster and Postherpetic Neuralgia: Changing Incidence Rates From 1994 to 2018 in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, e3210-e3217.	5.8	51
139	Skin Test. <i>Journal of the Dermatology Nurses' Association</i> , 2020, 12, 181-184.	0.1	0
140	Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa172.	0.9	6
141	Infections and systemic sclerosis: an emerging challenge. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2020, 27, 62-84.	0.0	1
142	Acute retinal necrosis following recombinant subunit varicella-zoster virus vaccine. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 20, 100962.	0.7	8
143	Immune response to varicella-zoster virus before and after renal transplantation. <i>Antiviral Research</i> , 2020, 183, 104938.	4.1	5
144	Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients. <i>ACR Open Rheumatology</i> , 2020, 2, 357-361.	2.1	43
145	Concerns about the safety of anti-TNF agents when treating rheumatic diseases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 695-705.	2.4	11
146	Shingles Vaccination of U.S. Adults Aged 50-59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine. <i>American Journal of Preventive Medicine</i> , 2020, 59, 21-31.	3.0	11
147	Diabetes mellitus as a vaccine-effect modifier: a review. <i>Expert Review of Vaccines</i> , 2020, 19, 445-453.	4.4	20
148	An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches. <i>Vaccine</i> , 2020, 38, 4060-4065.	3.8	2

#	ARTICLE	IF	CITATIONS
149	Vaccinations and Biologics. Infectious Disease Clinics of North America, 2020, 34, 425-450.	5.1	0
150	Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infectious Disease Clinics of North America, 2020, 34, 271-310.	5.1	4
151	Zoster vaccine in immunosuppressed populations. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 407-409.	1.5	1
152	New Developments in Bacterial, Viral, and Fungal Cutaneous Infections. Current Dermatology Reports, 2020, 9, 152-165.	2.1	7
153	FR-Nueva vacuna recombinante para la prevención del herpes zóster. Actas Dermo-sifiligráficas, 2020, 111, 67-68.	0.4	1
154	Effect of herpes zoster vaccine and antiviral treatment on risk of ischemic stroke. Neurology, 2020, 95, e708-e717.	1.1	13
155	Disseminated herpes zoster with cauda equina symptoms. IDCases, 2020, 21, e00902.	0.9	3
156	What's New in Vaccine Science. Primary Care - Clinics in Office Practice, 2020, 47, 517-528.	1.6	0
157	Updates in Adult Immunizations. Journal for Nurse Practitioners, 2020, 16, 218-223.	0.8	1
158	The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine. Journal of Infectious Diseases, 2021, 224, 1139-1146.	4.0	12
159	Correspondence regarding Wilson et al., cost-effectiveness of a comprehensive immunization program serving high-risk, uninsured adults. Preventive Medicine, 2020, 133, 105973.	3.4	0
160	Association of herpes zoster and chronic inflammatory skin disease in US inpatients. Journal of the American Academy of Dermatology, 2021, 85, 1437-1445.	1.2	12
161	Vaccination in Patients with Inflammatory Bowel Diseases. Digestion, 2020, 101, 58-68.	2.3	29
162	Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: Results from a claims database cohort study, from 2005 to 2014. Journal of Dermatology, 2020, 47, 236-244.	1.2	11
163	Postherpetic Neuralgia: Current Evidence on the Topical Film-Forming Spray with Bupivacaine Hydrochloride and a Review of Available Treatment Strategies. Advances in Therapy, 2020, 37, 2003-2016.	2.9	17
164	Optimizing Immunization Strategies in Patients with IBD. Inflammatory Bowel Diseases, 2021, 27, 123-133.	1.9	29
165	Varicella Zoster Virus in Inflammatory Bowel Disease Patients: What Every Gastroenterologist Should Know. Journal of Crohn's and Colitis, 2021, 15, 316-325.	1.3	5
166	High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults. Annals of Pharmacotherapy, 2021, 55, 89-97.	1.9	5

#	ARTICLE	IF	CITATIONS
167	Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 279-284.	5.8	8
168	Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIb, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients. <i>Vaccine</i> , 2021, 39, 6-10.	3.8	9
169	Pediatric Vaccines and Cost-Effectiveness Thresholds: How Much is Too Much to Pay for Prevention?. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1-13.	4.0	1
170	Impact of a pharmacist-driven recombinant zoster vaccine administration program. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e136-e139.	1.5	2
172	Update of the Mexican College of Rheumatology guidelines for the pharmacological treatment of rheumatoid arthritis, 2018. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 215-228.	0.3	2
173	The role of social determinants in timely herpes zoster vaccination among older American adults. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2043-2049.	3.3	11
174	Vascular Composite Allografts (VCA): New Transplants, New Infections. , 2021, , 1513-1532.		0
175	An Autopsy Case of Disseminated Varicella Zoster Virus Infection During the Treatment of Nephrotic Syndrome. <i>Internal Medicine</i> , 2021, , .	0.7	3
176	Vaccine Production, Safety, and Efficacy. , 2021, , 281-288.		3
177	Pneumonia and central nervous system infection caused by reactivation of varicella-zoster virus in a living-donor kidney transplantation patient: case report and review of the literature. <i>CEN Case Reports</i> , 2021, 10, 370-377.	0.9	6
178	A Comprehensive Review of Infections in Older Kidney Transplant Recipients. <i>Current Transplantation Reports</i> , 2021, 8, 90-99.	2.0	3
179	The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2050-2057.	3.3	5
180	Vaccines for older adults. <i>BMJ, The</i> , 2021, 372, n188.	6.0	36
181	Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older. <i>Vaccine</i> , 2021, 39, 926-932.	3.8	17
182	The Effectiveness of Recombinant Zoster Vaccine: Observations in the Wild. <i>Clinical Infectious Diseases</i> , 2021, 73, 957-960.	5.8	4
183	Update in Viral Infections in the Intensive Care Unit. <i>Frontiers in Medicine</i> , 2021, 8, 575580.	2.6	14
184	Applying the AFIX Quality Improvement Model to Increase Adult Immunization in Wisconsin. <i>Public Health Reports</i> , 2021, 136, 603-608.	2.5	2
185	Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 949-956.	5.8	34

#	ARTICLE	IF	CITATIONS
186	Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older – United States, 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 193-196.	15.1	23
187	Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure. <i>Clinical Infectious Diseases</i> , 2021, 73, 941-948.	5.8	45
188	Postlicensure herpes zoster vaccine effectiveness: systematic review protocol. <i>BMJ Open</i> , 2021, 11, e040964.	1.9	3
189	Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2021, 5, 1585-1593.	5.2	19
190	Recommended Adult Immunization Schedule, United States, 2021. <i>Annals of Internal Medicine</i> , 2021, 174, 374-384.	3.9	13
191	A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency. <i>Infectious Diseases and Therapy</i> , 2021, 10, 637-661.	4.0	13
192	Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 285-300.	3.0	12
193	The incidence of herpes zoster in patients with diabetes mellitus. <i>Medicine (United States)</i> , 2021, 100, e25292.	1.0	12
194	Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States. <i>Ophthalmology</i> , 2021, 128, 1699-1707.	5.2	18
195	Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2482-2487.	3.3	23
196	Immunizations in Chronic Kidney Disease and Kidney Transplantation. <i>Current Treatment Options in Infectious Diseases</i> , 2021, 13, 47-65.	1.9	9
197	Surveillance of Vaccination Coverage Among Adult Populations – United States, 2018. <i>MMWR Surveillance Summaries</i> , 2021, 70, 1-26.	34.6	159
198	Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model. <i>PLoS ONE</i> , 2021, 16, e0251644.	2.5	6
199	Vaccination Update for Nurse Practitioners Caring for Adults. <i>Advances in Family Practice Nursing</i> , 2021, 3, 15-39.	0.1	0
200	Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 36.	4.2	12
201	Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines. <i>Journal of Virology</i> , 2021, 95, .	3.4	18
202	Infections in Older Adults. <i>Emergency Medicine Clinics of North America</i> , 2021, 39, 379-394.	1.2	13
203	Adult preventive vaccines with other synergistic lifestyle options: is it time to add these ancillary benefits to the overall AS management checklist?. <i>World Journal of Urology</i> , 2021, , 1.	2.2	0

#	ARTICLE	IF	CITATIONS
204	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 880-895.	1.9	11
205	Herpes Zoster Vaccine Live and Risk of Stroke Among Medicare Beneficiaries. <i>Stroke</i> , 2021, 52, 1712-1721.	2.0	16
206	Vaccination Against Herpes Zoster and the Potential to Reduce the Global Burden of Stroke. <i>Stroke</i> , 2021, 52, 1722-1723.	2.0	0
207	Herpes Zoster: A Brief Definitive Review. <i>Cornea</i> , 2021, 40, 943-949.	1.7	13
208	Ageing and Options to Halt Declining Immunity to Virus Infections. <i>Frontiers in Immunology</i> , 2021, 12, 681449.	4.8	26
210	Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment. <i>Expert Review of Vaccines</i> , 2021, 20, 729-741.	4.4	6
211	Lupus, vaccinations and COVID-19: What we know now. <i>Lupus</i> , 2021, 30, 1541-1552.	1.6	21
212	Corneal Allograft Rejection Associated With Herpes Zoster Recombinant Adjuvanted Vaccine. <i>Cornea</i> , 2021, Publish Ahead of Print, .	1.7	12
213	Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study. <i>Vaccine</i> , 2021, 39, 3974-3982.	3.8	11
214	Management of cutaneous side effects of inflammatory bowel disease therapy: A dermatologic viewpoint. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	2.8	0
215	Estimated Public Health Impact of the Recombinant Zoster Vaccine. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 596-604.	2.4	3
216	Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2. <i>Vaccines</i> , 2021, 9, 572.	4.4	93
217	Intent to get vaccinated against COVID-19 among reproductive-aged women in Texas. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2914-2918.	3.3	20
218	Varicella-zoster virus early infection but not complete replication is required for the induction of chronic hypersensitivity in rat models of postherpetic neuralgia. <i>PLoS Pathogens</i> , 2021, 17, e1009689.	4.7	8
219	Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 812-822.	0.4	4
220	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. <i>World Journal of Gastroenterology</i> , 2021, 27, 4276-4297.	3.3	13
221	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)â€™Part 2: Inactivated Vaccines. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, e72-e91.	0.3	8
222	Efficacy of Recombinant Zoster Vaccine in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1570-1578.e1.	4.4	13

#	ARTICLE	IF	CITATIONS
223	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD) – Part 2: Inactivated Vaccines. <i>Gastroenterology</i> , 2021, 161, 681-700.	1.3	14
224	Herpes zoster epidemiology in Latin America: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0255877.	2.5	19
225	Awareness of diabetic adult patients about immunization. <i>Mã-Å¼narodnij Endokrinologã-Å½urnal</i> , 2021, 17, 273-279.	0.4	1
226	Insurance reimbursements for recombinant zoster vaccine in the private sector. <i>Vaccine</i> , 2021, 39, 5091-5094.	3.8	3
227	Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4265-4282.	3.3	6
228	Trigeminal Zoster with drug-induced labial angioedema leading to necrosis. <i>Medicine and Pharmacy Reports</i> , 0, , .	0.4	1
229	The impact of community pharmacy utilization of immunization information systems on vaccination rates: Results of a clustered randomized controlled trial. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 95-103.e2.	1.5	7
230	Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. <i>Gastroenterologã Y Hepatologã (English Edition)</i> , 2021, 44, 587-587.	0.1	1
231	Association Between Diabetes Mellitus and the Risk of Herpes Zoster: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 586-597.	3.6	13
232	A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations. <i>Expert Review of Vaccines</i> , 2021, 20, 1065-1075.	4.4	18
233	Herpes Zoster Vaccines. <i>Journal of Infectious Diseases</i> , 2021, 224, S429-S442.	4.0	61
234	Validation of algorithms using International Classification of Diseases for the identification of herpes zoster episodes requiring hospitalization in Quebec, Canada. <i>Vaccine</i> , 2021, 39, 6074-6080.	3.8	0
235	Riesgo de infecciã³n asociado a los inhibidores de las quinasas Janus (JAK) y las terapias biolã³gicas en enfermedad inflamatoria intestinal y artritis reumatoide. Estrategias de prevenciã³n. <i>Gastroenterologã Y Hepatologã</i> , 2021, 44, 587-598.	0.5	3
236	Increased Health Care Resource Utilization and Costs Associated with Herpes Zoster Among Patients Aged ≥50 Years with Chronic Obstructive Pulmonary Disease in the United States. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 502-516.	0.7	4
237	Immunization Strategies to Span the Spectrum of Immunocompromised Adults. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1530-1548.	3.0	5
239	Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older – United States, 2018. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 158-160.	15.1	38
240	<i>Notes from the Field:</i> Vaccine Administration Errors Involving Recombinant Zoster Vaccine – United States, 2017–2018. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 585-586.	15.1	11
241	Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) – United States, October 2017–June 2018. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 91-94.	15.1	37

#	ARTICLE	IF	CITATIONS
242	Solid Organ Transplantation in Older Adults. Infectious and Other Age-Related Considerations. OBM Transplantation, 2018, 3, 1-1.	0.2	2
243	Recombinant zoster vaccine (Shingrix [®]): a new option for the prevention of herpes zoster and postherpetic neuralgia. Korean Journal of Pain, 2020, 33, 201-207.	2.2	11
244	Zoster sine herpette: a review. Korean Journal of Pain, 2020, 33, 208-215.	2.2	36
245	The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease. Infection and Chemotherapy, 2020, 52, 252.	2.3	14
246	The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. Cleveland Clinic Journal of Medicine, 2020, 87, 695-703.	1.3	26
247	Radiotherapy Increases the Incidence of Herpes Zoster in Oral Cavity Cancer Patients – a National Population-based Cohort Study. In Vivo, 2021, 35, 3547-3553.	1.3	3
248	A Medical Records Review Study Assessing Safety of Zoster Vaccine Recombinant, Adjuvanted in Patients With Rheumatic Disease. Journal of Clinical Rheumatology, 2022, 28, e528-e531.	0.9	2
249	Infectious Keratitis in 2021. JAMA - Journal of the American Medical Association, 2021, 326, 1319.	7.4	21
250	Vaccine Coverage Across the Life Course in Michigan During the COVID-19 Pandemic: January–September 2020. American Journal of Public Health, 2021, 111, 2027-2035.	2.7	4
251	Shingles vaccination uptake in Massachusetts adults aged 50 years and older. Vaccine, 2021, 39, 6781-6786.	3.8	4
252	Chronic Myeloid Leukemia (CML) and Chronic Lymphocytic Leukemia (CLL). , 2017, , .		0
253	Vaccines and Biologics. , 2017, , .		0
255	New Herpes Zoster Vaccine: What the Hematologist Needs to Know. , 2018, 15, .		0
256	Immunisation. , 2019, , 19-169.		0
257	Herpes Zoster and the Zoster Eye Disease Study (ZEDS). , 2020, , 63-71.		0
258	Vaccination of Patients with Systemic Lupus Erythematosus. Korean Journal of Medicine, 2020, 95, 170-175.	0.3	0
259	Imunizaci3n en personal de salud. Acta Medica Costarricense, 2019, 61, .	0.1	0
260	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. American Journal of Hematology, 2022, 97, 90-98.	4.1	13

#	ARTICLE	IF	CITATIONS
261	Can SARS-CoV-2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 3350-3361.	1.6	31
262	Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries. <i>JAMA Internal Medicine</i> , 2021, 181, 1623.	5.1	26
263	Acute Retinal Necrosis and Progressive Outer Retinal Necrosis. , 2020, , 160-168.		0
264	Updates of adult immunization in Korea. <i>Journal of the Korean Medical Association</i> , 2020, 63, 128.	0.3	3
265	Infections in the Adult Solid Organ Transplant Recipient. , 2020, , 153-196.		1
266	Vascular Composite Allografts (VCA): New Transplants, New Infections. , 2020, , 1-20.		0
267	Varicella-Zoster Virus (Herpesviridae). , 2020, , 860-867.		0
268	Grouped Vesicles on an Erythematous Base. <i>Journal of the Dermatology Nurses' Association</i> , 2021, Publish Ahead of Print, .	0.1	0
269	The Practice Guideline for Vaccinating Korean Patients With Autoimmune Inflammatory Rheumatic Disease. <i>Journal of Rheumatic Diseases</i> , 2020, 27, 182-202.	1.1	2
270	Vascular Composite Allografts (VCA): New Transplants, New Infections. , 2021, , 1-21.		0
271	Shingrix: A New Herpes Zoster Vaccine. <i>P and T</i> , 2019, 44, 406-433.	0.9	8
272	Serious and Opportunistic Infections in Elderly Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 593-605.	0.1	2
273	Vaccination of Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic. <i>Gastroenterology and Hepatology</i> , 2021, 17, 18-30.	0.1	1
274	Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance. , 2021, 9, 251513552110574.	2.3	5
275	Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review. <i>International Ophthalmology</i> , 2022, 42, 689-711.	1.4	9
276	Select immunizations for adult women. <i>Menopause</i> , 2021, Publish Ahead of Print, 101-103.	2.0	1
277	Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. <i>JAMA Network Open</i> , 2021, 4, e2135362.	5.9	1
278	The nuclear and cytoplasmic activities of RNA polymerase III, and an evolving transcriptome for surveillance. <i>Nucleic Acids Research</i> , 2021, 49, 12017-12034.	14.5	21

#	ARTICLE	IF	CITATIONS
279	Risk of Guillain-Barré syndrome following herpes zoster, United States, 2010–2018. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5304-5310.	3.3	5
280	PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPITA). <i>Microorganisms</i> , 2022, 10, 127.	3.6	16
281	A Guide to Preclinical Models of Zoster-Associated Pain and Postherpetic Neuralgia. <i>Current Topics in Microbiology and Immunology</i> , 2021, , 189-221.	1.1	2
282	Equivalent Cellular and Humoral Immunity to Varicella Zoster Virus in Patients With Inflammatory Bowel Disease and Healthy Older Adults for Whom Immunization Is Recommended. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00446.	2.5	5
283	Strategies for successful designing of immunocontraceptive vaccines and recent updates in vaccine development against sexually transmitted infections - A review. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 2033-2046.	3.8	1
284	Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 80-84.	15.1	91
285	Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-5.	3.3	5
286	Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac011.	0.9	3
287	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2022. <i>Diabetes Care</i> , 2022, 45, S46-S59.	8.6	99
288	Importance of reasons for stocking adult vaccines. <i>American Journal of Managed Care</i> , 2019, 25, e334-e341.	1.1	1
289	A Review of Treatment for Herpes Zoster Keratitis. <i>US Ophthalmic Review</i> , 2021, 15, 43.	0.2	0
290	Herpes Zoster Ophthalmicus: A Devastating Disease Coming Back with Vengeance or Finding Its Nemesis?. <i>Journal of Ophthalmic and Vision Research</i> , 2022, 17, 123-129.	1.0	1
291	Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. , 2022, 10, 251513552210845.	2.3	16
292	Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine. <i>Case Reports in Ophthalmology</i> , 2022, 13, 104-108.	0.7	5
293	The Burden of Vaccine-preventable Diseases in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 798-804.	2.2	9
294	Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. <i>American Journal of Transplantation</i> , 2022, 22, 986-990.	4.7	6
295	Effect of Routine Varicella Immunization on the Epidemiology and Immunogenicity of Varicella and Shingles. <i>Viruses</i> , 2022, 14, 588.	3.3	6
296	Herpes zoster meningitis in a rheumatoid arthritis patient treated with tofacitinib. <i>BMJ Case Reports</i> , 2022, 15, e247276.	0.5	2

#	ARTICLE	IF	CITATIONS
297	Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors. <i>Translational Cancer Research</i> , 2022, 11, 456-462.	1.0	4
298	Knowledge and Attitudes Concerning Herpes Zoster among People with COPD: An Interventional Survey Study. <i>Vaccines</i> , 2022, 10, 420.	4.4	7
299	Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. <i>The Lancet Healthy Longevity</i> , 2022, 3, e263-e275.	4.6	19
300	Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017â€“2021. <i>Vaccine</i> , 2022, 40, 2266-2273.	3.8	5
301	Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	3.3	3
302	Vaccination in Chronic Liver Disease: An Update. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 937-947.	0.9	31
303	Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5296-5303.	3.3	8
305	An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21. <i>Npj Vaccines</i> , 2022, 7, 45.	6.0	7
306	Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-5.	3.3	2
307	Dermatomal rash after Shingrix vaccination: cause or coincidence?. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 686-687.	0.5	2
308	Does meta-analysis of economic evaluations have the potential to play a role in healthcare decision-making in the United States?. <i>Journal of Medical Economics</i> , 2022, 25, 750-754.	2.1	4
310	Letter to the Editor in Response to <i>Hall EW, Weng MK, Harris AM, et al. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults</i>. <i>Journal of Infectious Diseases</i> , 0, , .	4.0	0
311	Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immuneâ€“Mediated Inflammatory Diseases in the US. <i>Arthritis and Rheumatology</i> , 2022, 74, 1833-1841.	5.6	5
312	Clinical Nudge Impact on Herpes Zoster Vaccine Series Completion in Pharmacies. <i>American Journal of Preventive Medicine</i> , 2022, 63, 582-591.	3.0	6
314	Comparing Prodrugs with Acyclovir for Treating Postherpetic Neuralgia among Herpes Zoster Patients: A Systematic Review and Meta-Analysis. <i>Healthcare (Switzerland)</i> , 2022, 10, 1181.	2.0	6
315	<i>Serious Infections</i> . , 2022, , 297-309.		0
316	<i>Screening and Prevention</i> . , 2022, , 33-43.		0
317	<i>Dermatologic Conditions</i> . , 2022, , 457-476.		0

#	ARTICLE	IF	CITATIONS
318	Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine. <i>Journal of General Internal Medicine</i> , 2023, 38, 986-993.	2.6	4
319	Infectious issues of therapeutic monoclonal antibodies in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Clinical and Experimental Neuroimmunology</i> , 0, , .	1.0	0
320	Neurologic Problems. , 2022, , 189-207.		1
321	Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM). <i>ESMO Open</i> , 2022, 7, 100548.	4.5	7
322	Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review. <i>Preventive Medicine Reports</i> , 2022, 29, 101923.	1.8	1
323	Immunization for midlife women. <i>Menopause</i> , 0, Publish Ahead of Print, .	2.0	1
324	Health Care Professionalsâ€™ Herpes Zoster Awareness and Vaccine Recommendations for Patients with COPD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 0, , .	0.7	0
325	Approaches to vaccine prevention in multiple sclerosis. <i>Zhurnal Nevrologii I Psikhiiatrii Imeni S S Korsakova</i> , 2022, 122, 29.	0.7	1
326	Vaccines for the Elderly. <i>Quality of Life in Asia</i> , 2022, , 83-104.	0.2	0
327	Modeling the Impact of Exogenous Boosting and Universal Varicella Vaccination on the Clinical and Economic Burden of Varicella and Herpes Zoster in a Dynamic Population for England and Wales. <i>Vaccines</i> , 2022, 10, 1416.	4.4	4
328	Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials. <i>Pain</i> , 2023, 164, 741-748.	4.2	4
329	Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 338-351.	1.3	22
330	Utilization of preventive services in a systemic lupus erythematosus population-based cohort: a Lupus Midwest Network (LUMEN) study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	4
331	Herpes zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in New Zealand: a retrospective cohort study. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 31, 100601.	2.9	5
332	Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	9
333	Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis. <i>Diabetes Care</i> , 2022, 45, 2585-2593.	8.6	4
334	Live attenuated VZV vaccination induces antitumor immunity in ATLL patients. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	1
335	Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data. <i>American Journal of Epidemiology</i> , 2023, 192, 205-216.	3.4	2

#	ARTICLE	IF	CITATIONS
336	Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years. <i>Value in Health</i> , 2023, 26, 204-215.	0.3	2
337	Sexual Orientation and Gender Identity Differences in Influenza, Shingles, and Pneumococcal Vaccination Among U.S. Older Adults. <i>LGBT Health</i> , 2023, 10, 138-147.	3.4	2
338	Association of asthma and herpes zoster, the role of vaccination: A literature review. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	2.7	2
339	Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical Trials. <i>Infectious Diseases and Therapy</i> , 2022, 11, 2265-2277.	4.0	5
340	Factors associated with pneumococcal vaccine uptake among vulnerable older adults in the United States primary care setting. <i>Vaccine</i> , 2022, 40, 6756-6766.	3.8	0
341	Hospitalization Burden Related to Herpes Zoster Infection in Spain (2016–2019). <i>Infectious Diseases and Therapy</i> , 0, , .	4.0	2
342	Herpes Zoster in Hospitalized Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 0, Publish Ahead of Print, .	2.2	0
343	Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50–64 years old in the United States. <i>Vaccine</i> , 2023, 41, 49-60.	3.8	3
344	Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50–64 years in the United States. <i>Vaccine</i> , 2022, 40, 7187-7190.	3.8	3
345	Varicella-Zoster Virus. , 2023, , 1084-1092.e2.		0
346	CD19, CD20 and CD52. , 2022, , 113-151.		0
347	Anti-tumor Necrosis Factor-Alpha Agents. , 2022, , 69-87.		0
348	Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions. <i>Vaccine</i> , 2023, 41, 36-48.	3.8	9
349	Advocating for Pharmacist Provider Status in the U.S. Healthcare System. <i>Advances in Healthcare Information Systems and Administration Book Series</i> , 2022, , 139-153.	0.2	0
350	Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines. <i>Viruses</i> , 2022, 14, 2667.	3.3	7
351	Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: A retrospective United States claims database analysis. <i>Clinical Respiratory Journal</i> , 2022, 16, 826-834.	1.6	5
352	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023. <i>Diabetes Care</i> , 2023, 46, s49-s67.2.	8.6	58
353	Economic burden of herpes zoster in Latin America: A systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	3.3	1

#	ARTICLE	IF	CITATIONS
354	Novel BCO2 Compound Adjuvant Enhances Adaptive and Innate Immunity Induced by Recombinant Glycoprotein E of Varicella-Zoster Virus. <i>Vaccines</i> , 2022, 10, 2155.	4.4	2
355	Epidemiology of Varicella Zoster Virus and Herpes Zoster Virus in Gulf Cooperation Council Countries: A Review of the Literature. <i>Infectious Diseases and Therapy</i> , 2023, 12, 81-93.	4.0	3
356	Clinical features of hospitalized herpes zoster patients and comparison of elderly patients with younger patients: tertiary care clinical experience.. <i>Ankara EÄÿitim Ve AraÄÿtÄ±rma Hastanesi TÄ±p Dergisi</i> , 0, , .	0.2	0
357	Expert consensus on vaccination in patients with inflammatory bowel disease in Japan. <i>Journal of Gastroenterology</i> , 2023, 58, 135-157.	5.1	1
359	<scp>Costâ€effectiveness</scp> of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 1326-1334.	3.7	5
360	Highlights into historical and current immune interventions for cancer. <i>International Immunopharmacology</i> , 2023, 117, 109882.	3.8	2
361	Herpesvirus-Related Lesions of the Oral Mucosa. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2023, 35, 175-187.	1.0	1
362	Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?. <i>Respiratory Research</i> , 2023, 24, .	3.6	7
363	Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients. <i>Viruses</i> , 2023, 15, 439.	3.3	12
364	Abdominal paresis and pseudo-hernia secondary to herpes zoster infection: A case report and systematic analysis. <i>Heliyon</i> , 2023, 9, e13578.	3.2	2
365	Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	2
366	Vaccine-Preventable Diseases in Older Adults. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 103-121.	5.1	3
367	Italian guidance on Dementia Day Care Centres: AÂposition paper. <i>Aging Clinical and Experimental Research</i> , 2023, 35, 729-744.	2.9	2
368	How large could the public health impact of introducing recombinant zoster vaccination for people aged â‰¥50 years in five Latin American countries be?. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	2
369	Public health impact of herpes zoster vaccination on older adults in Hong Kong. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
370	Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	2
371	Acceptability of Herpes Zoster Vaccination among Patients with Diabetes: A Cross-Sectional Study in Saudi Arabia. <i>Vaccines</i> , 2023, 11, 651.	4.4	2
372	Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	8

#	ARTICLE	IF	CITATIONS
373	Review of an Unusual Case of Chronic Relapsing (A–6) Zoster Sine Herpete: Immediate Response to High-dose Oral Acyclovir Therapy: Efficacy of the Expedited Classic Therapeutic Trial in an Era of Digital Medicine. , 0, Volume 2, 1-18.		0
374	Immunogenicity and safety of the non-typable <i>Haemophilus influenzae</i> “ <i>Moraxella catarrhalis</i> (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial. <i>Human Vaccines and Immunotherapeutics</i> . 2023. 19. .	3.3	0
375	Vaccines and the Prevention of Dermatologic Diseases. , 2023, , 1501-1520.		0
376	Vaccination in liver diseases and liver transplantation: Recommendations, implications and opportunities in the post-COVID era. <i>JHEP Reports</i> , 2023, 5, 100776.	4.9	3
377	Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data. <i>Vaccine</i> , 2023, 41, 3493-3496.	3.8	1
378	Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines. <i>Journal of Infectious Diseases</i> , 0, , .	4.0	2
379	Understanding Over-immunization in North Dakota's Adult Population. <i>Journal of Public Health Management and Practice</i> , 0, Publish Ahead of Print, .	1.4	0
380	Top 100 Most-Cited Papers in Herpes Zoster from 2000 to 2022: A Bibliometric Study. <i>Journal of Pain Research</i> , 0, Volume 16, 1779-1797.	2.0	2
381	Factors influencing herpes zoster vaccination among older people in China: results from a discrete choice experiment. <i>Public Health</i> , 2023, 220, 33-34.	2.9	0
383	Efficacy and effectiveness of Herpes zoster vaccination in adults with diabetes mellitus: a systematic review and meta-analysis of clinical trials and observational studies. <i>Acta Diabetologica</i> , 0, , .	2.5	1
384	Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2023, 21, 845-851.	0.8	0
385	Clinical and economic implications of increasing access to herpes zoster vaccination rate in community pharmacies. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2023, , .	1.5	0
386	Ageing and Rabies Prophylaxis. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	1
387	Mind the Gap – A Perspective on Strategies for Protecting against Bacterial Infections during the Period from Infection to Eradication. <i>Microorganisms</i> , 2023, 11, 1701.	3.6	1
388	Risk of herpes zoster following mRNA COVID-19 vaccine administration. <i>Expert Review of Vaccines</i> , 2023, 22, 643-649.	4.4	3
389	Immunization in midlife. , 0, , .		0
390	Zoster Vaccines. , 2023, , 1334-1349.e7.		0
391	Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T cell therapy. <i>Transplant Infectious Disease</i> , 2023, 25, .	1.7	2

#	ARTICLE	IF	CITATIONS
392	The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50–59 years. <i>Vaccine</i> , 2023, 41, 5360-5367.	3.8	2
393	Heterogeneity of memory T cells in aging. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
394	Provider Vaccine Hesitancy in the Setting of Recurrent Herpes Zoster. <i>Journal for Nurse Practitioners</i> , 2023, 19, 104761.	0.8	0
395	Burden of Herpes Zoster Among Patients with Psoriasis in the United States. <i>Dermatology and Therapy</i> , 2023, 13, 2649-2668.	3.0	1
396	Hospitalization burden related to herpes zoster infection during the COVID-19 pandemic in Spain (2020-2021). <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	1
397	Herpes zoster vaccination recommendations of the group of experts of the Polish Society of Vaccinology, the Polish Society of Family Medicine, the Polish Society of Dermatology, the Polish Association for the Study of Pain and the Polish Neurological Society. <i>BMC</i> , 2023, 24, 14-21.	0.1	0
398	REPRINTED WITH PERMISSION OF IASP PAIN 164 (2023) 741748: Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials. <i>BMC</i> , 2023, 24, 22-33.	0.1	0
399	COVID-19 and herpes zoster: a call to action. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	3
400	Handlungsempfehlungen zur Risikominimierung beim Einsatz von Januskinase-Inhibitoren zur Therapie chronischer entzündlicher Hauterkrankungen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2023, 21, 845-852.	0.8	0
401	Diagnostic Methods and Management Strategies of Herpes Simplex and Herpes Zoster Infections. <i>Clinics in Geriatric Medicine</i> , 2024, 40, 147-175.	2.6	1
402	Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records. <i>BMJ, The</i> , 0, , e076321.	6.0	5
403	Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	2
404	Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States. <i>Pharmacoeconomics - Open</i> , 0, , .	1.8	0
405	Vaccine-Preventable Illness Leads to Adverse Outcomes in Liver Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2024, 69, 588-595.	2.3	0
406	Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in Miyun District of Beijing, China: An EQ-5D survey. <i>Vaccine: X</i> , 2023, 15, 100415.	2.1	0
407	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes 2024. <i>Diabetes Care</i> , 2024, 47, S52-S76.	8.6	1
408	Post-herpetic Neuralgia (PHN)., 2023, , 213-219.		0
409	Human Herpesviruses: Varicella and Herpes Zoster. , 2024, , 1-59.		0

#	ARTICLE	IF	CITATIONS
410	A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan. <i>Vaccine</i> , 2024, 42, 464-470.	3.8	0
411	Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. <i>Annals of Internal Medicine</i> , 2024, 177, 189-195.	3.9	0
412	Assessment of the Level of Knowledge and Attitude Towards Herpes Zoster and Its Vaccination Among Individuals at Risk in Saudi Arabia. <i>Cureus</i> , 2024, , .	0.5	0
413	Herpes zoster vaccination and the risk of dementia: A systematic review and meta-analysis. <i>Brain and Behavior</i> , 2024, 14, .	2.2	0
414	Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice. <i>Indian Journal of Gastroenterology</i> , 2024, 43, 22-35.	1.4	0
416	Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): Recommended Immunization Schedule (2023) and Update on Immunization for Children Aged 0 Through 18 Years. <i>Indian Pediatrics</i> , 2024, 61, 113-125.	0.4	0
417	Herpes Zoster Recurrence: A Narrative Review of the Literature. <i>Dermatology and Therapy</i> , 2024, 14, 569-592.	3.0	0
418	Knowledge, attitude, and practice toward herpes zoster (HZ) and HZ vaccination: Concept elicitation findings from a multi-country study in the Asia Pacific. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 20, .	3.3	0
419	Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 20, .	3.3	0
420	Baculovirus Vector-Based Varicella-Zoster Virus Vaccine as a Promising Alternative with Enhanced Safety and Therapeutic Functions. <i>Vaccines</i> , 2024, 12, 333.	4.4	0